Cytosorbents (CTSO) Restructuring Costs (2024 - 2026)

Cytosorbents (CTSO) has 3 years of Restructuring Costs data on file, last reported at $6.6 million in Q1 2026.

• For the quarter ending Q1 2026, Restructuring Costs fell 5.12% year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $156000.0 (down 99.4% YoY), and the FY2025 full-year result was $510000.0, down 98.03% from the prior year.
• Restructuring Costs for Q1 2026 stood at $6.6 million, up from -$20.4 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $7.1 million in Q2 2025 and bottomed at -$20.4 million in Q4 2025.
• The 3-year median for Restructuring Costs is $6.6 million (2026), against an average of $3.7 million.
• Peak annual rise in Restructuring Costs reached 14.01% in 2025, while the deepest fall reached 415.01% in 2025.
• A 3-year view of Restructuring Costs shows it stood at $6.5 million in 2024, then sank by 415.01% to -$20.4 million in 2025, then surged by 132.17% to $6.6 million in 2026.
• The last three Restructuring Costs figures came in at $6.6 million (Q1 2026), -$20.4 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.

Peer Comparison